Clinicians prescribing GLP-1 agents should ask about sexual function and consider medication review if new anorgasmia appears.

Thirteen drugs for cancer and diabetes have been added to the list of essential medicines exempted from value-added tax or VAT, according to the Food and Drug Administration (FDA). Cancer drugs ...

The results were published in The New England Journal of Medicine as part of the OASIS 4 phase 3 trial. The findings show ...

Experimental pill versions of GLP-1 weight loss drugs by Novo Nordisk and Eli Lilly will receive FDA priority review. Read ...

This article was reviewed by Darragh O’Carroll, MD. Oral vs. Injectable Semaglutide: Effectiveness & Side Effects Key ...

The SOUL trial, published in the New England Journal of Medicine, tracked 9,650 adults with type 2 diabetes and elevated cardiovascular risk over nearly four years.

The FDA has approved Rybelsus, the first oral GLP-1 receptor agonist, to reduce cardiovascular risk in type 2 diabetes ...

Despite success with injectable drugs pharma companies are investing heavily in tablets, long considered the holy grail of ...

The idea was beautifully simple. One pill taken daily to melt away those excess pounds. The new breed of GLP-1 oral ...

Novo Nordisk's Rybelsus gets US FDA approval for CV risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event: Plainsbo ...

PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Oct. 17, 2025 /PRNewswire/ -- Novo Nordisk announced today that the US Food and Drug Administration (FDA) has approved Rybelsus ®, the only oral GLP-1 ...

Rybelsus ® (semaglutide) tablets 7 mg or 14 mg, the only FDA-approved oral GLP-1 medicine available, now indicated to reduce the risk of major adverse cardiovascular events (MACE) such as CV death, ...